Pharma: Page 2
-
Dive Awards
The BioPharma Dive Awards for 2019
A busy year brought an upswing in a storied pharma's fortunes, an industry-shaking mega-merger and the surprise revival of an Alzheimer's drug.
-
Myeloma cell therapies, now in pharma hands, move into spotlight
Long-awaited results from Bristol-Myers and Bluebird position the drugmakers to win a first-in-class CAR-T approval. Rival J&J, however, appears close behind.
By Ned Pagliarulo • Dec. 07, 2019 -
Novartis highlights 4 drugs of future in laying out R&D vision
With more than 160 drugs in clinical testing, Novartis executives highlighted a few lesser-known therapies they will prioritize in the next few years.
By Andrew Dunn • Dec. 05, 2019 -
Lilly puts its cancer future in Loxo's hands
Nearly a year on from buying Loxo for $8 billion, Lilly hopes to recast its cancer research more in the mold of the nimbler biotech.
By Ned Pagliarulo • Dec. 05, 2019 -
New approval for Roche's Tecentriq heats up lung cancer battle with Keytruda
One Wall Street analyst expects the FDA's OK will help Tecentriq outpace Bristol-Myers Squibb's Opdivo in 2020 in the non-small cell lung cancer market.
By Jonathan Gardner • Dec. 04, 2019 -
Deep DiveWill sky-high drug prices spur the US to use an obscure power over patents?
New cell therapies as well as gene-based treatments like Zolgensma benefited from NIH funding of early-stage research. Advocates say the time is now for the government to invoke its "march-in" rights.
By Jonathan Gardner • Dec. 04, 2019 -
Opioid makers subject of US grand jury probe
At least six companies have been subpoenaed in an investigation characterized as a wide probe into practices required under the Controlled Substances Act.
By Jonathan Gardner • Nov. 27, 2019 -
Medicines Co. deal caps pharma's reentry into field it once abandoned
Large pharma companies like Novartis, Roche and J&J are buying back into RNAi, a technology that several retreated from in the early 2010s.
By Ned Pagliarulo • Nov. 26, 2019 -
Roche SMA therapy granted speedy FDA review; decision by May 2020
A quick approval of risdiplam, an oral therapy, could challenge Biogen and Novartis in a field that just three years ago had no treatment options.
By Andrew Dunn • Nov. 25, 2019 -
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Acquiring The Medicines Company gives Novartis access to inclisiran, a lipid-lowering drug likely to win approval but facing uncertain commercial prospects.
By Ned Pagliarulo • Nov. 24, 2019 -
Calquence OK boosts AstraZeneca's challenge to Imbruvica
The new FDA approval expands Calquence's use into a more common blood cancer, although doctors have already been prescribing it for that disease.
By Jonathan Gardner • Nov. 22, 2019 -
AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron
The R&D chief believes researchers will discover a new drug target using machine learning within the next two or three years.
By Ned Pagliarulo • Nov. 21, 2019 -
Takeda sees cell, gene therapy in its future. Is it too late?
Nearly a year on from completing its $62 billion Shire deal, Takeda is pitching investors on its plans to stay one of the industry's leading rare disease drug developers.
By Ned Pagliarulo • Nov. 20, 2019 -
Deep DiveBankrupt biopharmas are rare. 2019 has some worried that's changing.
Eleven biopharmas declared bankruptcy in 2019, more than any other year since at least 2011. Rising market pressures, coupled with legal liabilities, risk more companies falling to zero, experts warn.
By Andrew Dunn • Nov. 19, 2019 -
Deep DiveThe running list of 2019 biopharma bankruptcies
From antibiotic developers like Achaogen to opioid drugmakers like Purdue and Insys, 2019 saw an uptick in biopharmas filing for Chapter 11.
By Andrew Dunn • Nov. 19, 2019 -
Deep Dive31 biopharmas at high risk of bankruptcy in 2020
BioPharma Dive dug into data from a credit monitoring firm to identify drugmakers at high risk of going bankrupt, including companies like Teva, Bausch Health and Novavax.
By Andrew Dunn • Nov. 19, 2019 -
Novartis reshapes China R&D hub to reflect rapidly evolving market
The Swiss pharma giant is ending drug discovery efforts and shifting resources toward early development and commercial activities, a move that will eliminate around 150 jobs in the near term.
By Jacob Bell • UPDATED: Nov. 18, 2019 at 2:19 p.m. -
Novartis sickle cell drug wins FDA approval
Adakveo is only the second treatment approved in two decades for the painful blood clots caused by the rare disease.
By Jonathan Gardner • Nov. 15, 2019 -
Novartis' Sandoz builds global generics presence with Japan acquisition
Sandoz will pay approximately $331 million upfront for a Japan-focused subsidiary of Aspen Pharmacare.
By Andrew Dunn • Nov. 11, 2019 -
5 updates from Teva's busy quarter: A new CFO, a biosimilar launch and a migraine miss
Teva's stock went in an unfamiliar direction Thursday — up — as the pharma slightly beat Wall Street sales expectations with its quarterly results.
By Andrew Dunn • Nov. 07, 2019 -
AstraZeneca's China ambitions grow with new R&D investments
Already a leader in China, the British pharma is doubling down with plans to open two new centers and launch a $1 billion biotech investment fund.
By Jonathan Gardner • Nov. 06, 2019 -
Strong sales buoy pharma even as risks grow
Pfizer and Merck are the latest large drugmakers to post better-than-expected third quarter sales, a picture of strength that belies rising threats to the industry.
By Ned Pagliarulo • Oct. 29, 2019 -
Pfizer's heart drug impresses with fast US launch
Vyndaqel sales contributed to a 7% jump in the pharma's core drugs business, though overall third quarter sales fell compared to the same period a year ago.
By Andrew Dunn • Oct. 29, 2019 -
AstraZeneca joins Bristol-Myers' run at Merck in lung cancer
Imfinzi plus chemotherapy kept patients from progressing as quickly as chemo alone in a key study, but oncologists will need to see survival and safety data.
By Jonathan Gardner • Oct. 28, 2019 -
Allergan pays $750M to rid itself of Namenda antitrust charges
A class action suit followed the New York attorney general in claiming the big pharma tried to delay generic competition to its Alzheimer's drug.
By Jonathan Gardner • Oct. 28, 2019
Previous
